公开(公告)号：US11786498B2

公开(公告)日：2023-10-17

申请号：US15737985

申请日：2015-07-02

Applicant: Novartis AG

Inventor： David Hook ,  Bin Hu ,  Florian Karl Kleinbeck ,  Ulrich Meier ,  Sibylle Mueller ,  Jean-Paul Mutz ,  Jan Schlomach ,  Paul Allen Sutton ,  Liladhar Murlidhar Waykole ,  Bernhard Wietfeld

IPC: A61K31/22 ,  A61P9/10 ,  A61P9/06 ,  A61P25/02 ,  C07C229/34 ,  A61P9/12 ,  A61P25/06 ,  A61K31/4178 ,  A61K31/423

CPC classification number: A61K31/22 ,  A61P9/06 ,  A61P9/10 ,  A61P9/12 ,  A61P25/02 ,  A61P25/06 ,  C07C229/34 ,  A61K31/4178 ,  A61K31/423 ,  A61K2300/00 ,  C07B2200/13

Abstract: The invention relates to polymorphic forms of the calcium salt of N-(3-carboxyl-1-oxopropyl)-(4S)-(p-phenylphenylmethyl)-4-amino-(2R)-methyl butanoic acid ethyl ester. The calcium salt of N-(3-carboxyl-1-oxopropyl)-(4S)-(p-phenylphenylmethyl)-4-amino-(2R)-methyl butanoic acid ethyl ester is useful in the treatment of various conditions and disorders responsive to the inhibition of neutral endopeptidases.

公开(公告)号：US20180344679A1

公开(公告)日：2018-12-06

申请号：US16006252

申请日：2018-06-12

Applicant: Novartis AG

Inventor： Lili Feng ,  Sven Erik Godtfredsen ,  Paul Allen Sutton ,  Mahavir Prashad ,  Michael J. Girgis ,  Bin Hu ,  Yugang Liu ,  Thomas J. Blacklock ,  Piotr Henryk Karpinski

IPC: A61K31/216 ,  C07D207/50 ,  C07D257/04 ,  C07C233/47 ,  A61K31/5415 ,  A61K31/41 ,  A61K31/4422 ,  A61K45/06

CPC classification number: A61K31/216 ,  A61K31/41 ,  A61K31/4422 ,  A61K31/5415 ,  A61K45/06 ,  A61K2300/00 ,  C07C233/47 ,  C07D207/50 ,  C07D257/04

Abstract: A method for treatment of a cardiovascular or renal condition or disease with a specific combination, linked pro-drug or a compound of an angiotensin receptor antagonist and a NEPi.